ABBV vs BLK: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and BlackRock, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-21.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
BlackRock, Inc. · Financial Services
$1,069.78
+44.0% upside to fair value
High Conviction
Grade A
High Quality
QuantHub Verdict
BLK has more upside to fair value
(+44.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
BLK |
| Current Price |
$261.70 |
$1,069.78 |
| Fair Value Estimate |
$259.04 |
$1,540.94 |
| Upside to Fair Value |
-1.0%
|
+44.0%
|
| Market Cap |
$462.4B |
$165.8B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
15.9x
|
| Price / Sales |
7.2x
|
6.1x
|
| Price / FCF |
23.6x
|
71.5x
|
| Revenue Growth YoY |
+10.2%
|
+30.6%
|
| Gross Margin |
71.5%
|
55.7%
|
| Operating Margin |
29.3%
|
31.1%
|
| Return on Equity |
-136.5%
|
11.7%
|
| Dividend Yield |
2.61% |
2.09% |
| FCF Yield |
4.25%
|
1.4%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
BlackRock is the world's largest asset manager, overseeing $15.345 trillion in assets across ETFs, active strategies, alternatives, and the Aladdin investment-technology platform, serving institutional, intermediary, and individual clients globally. The business quality is high: TTM gross margin of 55.7%, operating margin of 31.1%, and net margin of 24.1% reflect the scalability of a fee-based mo…
Accumulation Zones
| Metric |
ABBV |
BLK |
| Zone Low |
$194.28 |
$1,155.70 |
| Zone High |
$220.18 |
$1,309.80 |
| In Buy Zone? |
No
|
Yes
|